89.13MMarket Cap-1315P/E (TTM)
2.080High1.910Low216.77KVolume1.970Open1.970Pre Close431.40KTurnover0.85%Turnover RatioLossP/E (Static)44.56MShares8.19452wk High1.00P/B50.92MFloat Cap1.58052wk Low--Dividend TTM25.46MShs Float23.990Historical High--Div YieldTTM8.63%Amplitude1.390Historical Low1.990Avg Price1Lot Size
Werewolf Therapeutics Stock Forum
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Werewolf Therapeutics (HOWL) presented interim Phase 1 clinical trial results for WTX-330, their tumor-activated IL-12 prodrug, at SITC's 39th Annual Meeting. The trial enrolled 25 patients with diverse solid tumors, showing favorable tolerability and encouraging efficacy. Key findings include a confirmed partial response in a ...
4 mins ago
Werewolf Therapeutics Announces Promising New Development Candidate, Wtx-921, a First-of-Its-Kind Il-10 Indukine™ Molecule for Inflammatory Diseases
📊⚡️📊
📊⚡️📊
No comment yet